Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 701 - 750 out of 103,184

Document Document Title
WO/2014/060501A1
The invention relates to an agent for treating migraines or migraine pain. The invention also relates to an agent for the preventative treatment of chronic migraines or chronic migraine pain. According to the invention, the agent contain...  
WO/2014/061676A1
Provided is a compound useful as a prophylactic or therapeutic agent for neurodegenerative diseases and others or a salt of the compound. The present invention relates to a compound represented by formula (I) [wherein each symbol is as d...  
WO/2014/060371A1
The present invention relates to the use of novel compounds of formula I: wherein all variable substituents are defined as described herein, which are SYK inhibitors and are useful for the treatment of auto-immune and inflammatory diseases.  
WO/2014/059512A1
In an aspect, a formulation is provided that comprises at least one active substance and at least one coat comprising Eudragit E (dimethylaminoethyl methacrylate copolymer), wherein the formulation is free of any active substance externa...  
WO/2014/061764A1
A compound having an exceptional blood-sugar-reducing effect and represented by general formula (I), and a pharmaceutically acceptable salt thereof. In the formula, X is =C(R8)-, -CH(R8)-, =N-, or -O-; Y is =C(R9)-, -CH(R9)-, or =N-; Z i...  
WO/2014/062044A1
Invention is related to novel compounds - fluorinated benzenesulfonamides of general formula (I). The compounds can be used in biomedicine as active ingredients in pharmaceutical formulations, because they inhibit enzymes which participa...  
WO/2014/059558A1
The present invention provides a composition comprising nalbuphine prodrug-Sebacoyl dinalbuphine ester and pharmaceutical biodegradable polymer PLGA. The composition is prepared as a controlled release formulation, which can be implanted...  
WO/2014/059702A1
Disclosed are benfotiamine polymorphs, preparation method and use thereof. The crystal forms of benfotiamine are A crystal form benfotiamine, B crystal form benfotiamine, C crystal form benfotiamine, D crystal form benfotiamine or E crys...  
WO/2014/061735A1
 Provided is an improved β-subunit of human β-hexosaminidase, having activity derived from a α-subunit of wild-type human β-hexosaminidase, and having resistance to protease. A protein comprising, in the amino acid sequence for a...  
WO/2014/060113A1
The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or ...  
WO/2014/060432A1
New pyrrolotriazinone derivatives having the chemical structure of formula (I), are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Phosphoinositi...  
WO/2014/063087A1
A synergistic therapeutic effect is obtained in CNS cancer patients treated concomitantly with a first antineoplastic agent and a second antineoplastic agent, wherein one or both antineoplastic agents are administered by convection enhan...  
WO/2014/059383A1
The present invention provides compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting kinase (e.g., GSK3 (e.g., GSK3a or GS...  
WO/2014/058736A1
The present disclosure is generally directed to neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids as referenced herein, and pharmaceutically acceptable salts thereof, for use as, for example, an anesthetic, and/or in the tre...  
WO/2014/057484A1
An isolated peptide comprising a Huntingtin (Htt) amino acid sequence being no longer than 15 amino acids, wherein said Htt amino acid sequence comprises the sequence X X 2 X 3 X 4 X, wherein X is a hydrophobic amino acid or threonine, X...  
WO/2014/057772A1
The present invention provides a novel method for treating Alzheimer's disease. A compound expressed by general formula (I) or a salt thereof.  
WO/2014/058742A1
This invention discloses a treatment for a patient receiving medication to treat an attention deficit disorder such as ADHD wherein the treatment results in a loss of appetite and impairment of the patient's attentiveness. The treatment ...  
WO/2014/059295A1
Disclosed are methods and compositions for the treatment or prevention of vascular cognitive impairment. The disclosed methods and compositions include rapamycin, a rapamycin analog, or another such inhibitor of the target of rapamycin (...  
WO/2014/059185A1
The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A4, A5, A6, A8, R1, R2, R3, R7 and n of Formula I, inde...  
WO/2014/059115A1
Provided herein are methods, assays and compositions relating to the treatment of neurological diseases and disorders, particularly by modulating expression and/or activity of Bif-1.  
WO/2014/057179A1
The invention concerns a gaseous composition containing gaseous xenon for use by inhalation in order to prevent or treat at least one neurological consequence secondary to a septic shock in a patient.  
WO/2014/059306A1
The present invention relates to pyrimidine hydroxy amide compounds, and the use of such compounds in the inhibition of HDAC6 and in the treatment of depression and/or anxiety.  
WO/2014/057995A1
The objective of the present invention is to provide an extract from inflamed rabbit skin inoculated with vaccinia virus and formulations, etc. including the extract which have greater uniformity in quality. By using the amount of N-acet...  
WO/2014/058071A1
The present invention provides a compound that: has a lysine-specific demethylase-1-inhibiting effect; and provides utility as a drug for preventing or treating schizophrenia, Alzheimer's disease, Parkinson's disease, and Huntington chor...  
WO/2014/057266A1
The present invention relates to novel compounds of Formula I capable of inhibiting tissue transglutaminase, and uses of the same in medicine. In particular, the invention provides compounds for use in the treatment of prevention of dise...  
WO/2014/058875A3
Methods and compositions for enhancing one or more of: myelination, re-myelination, oligodendrocyte numbers, or neuroaxonal protection, while ameliorating an inflammatory condition in a human subject are disclosed. In certain embodiments...  
WO/2014/059346A1
Disclosed embodiments are related to pharmaceutical compositions and methods for preventing or treating conditions involving dopamine, such as Parkinson's disease, comprising administering to a mammal in need thereof, an effective amount...  
WO/2014/058160A1
According to the present invention, a composition comprising myricetin or a pharmaceutically acceptable salt thereof as an active ingredient enhances exercise performance and physical strength. Also, the composition has an anti-aging fun...  
WO/2014/057178A1
The invention concerns a gaseous composition containing gaseous argon for use by inhalation in order to prevent or treat at least one neurological consequence secondary to a septic shock in a patient.  
WO/2014/057727A1
The purpose is to provide a method for manufacture a fraction containing nobiletin and tangeretin in high concentration and having excellent safety, economic efficiency, and commercialization. The above-stated purpose is achieved by a me...  
WO/2014/059031A2  
WO/2014/059220A1
The invention provides, inter alia, immunoinhibitory glycosphingolipids and immunoinhibitory alpha-galactosylceramides and compositions and preparations thereof, and methods of use thereof including in the treatment of conditions charact...  
WO/2014/056620A1
The invention relates to certain compounds for the use in the treatment and/or prophylaxis of diseases and/or disorders that are, at least partially, mediated by TSPO activity.  
WO/2014/057997A1
The present invention provides: a method for producing a pluripotent spheroid cell, said method comprising introducing a reprogramming peptide containing a nuclear localization signal into a differentiated cell; a preparation for inducin...  
WO/2014/056779A1
The invention relates to a drug for the prophylaxis and/or treatment of a neurodegenerative disease.  
WO/2014/057180A1
The invention concerns a gaseous composition containing a mixture of gaseous xenon and argon for use by inhalation in order to prevent or treat at least one neurological consequence secondary to a septic shock in a patient.  
WO/2014/057362A3
The present invention relates to compositions comprising omega-3 fatty acid derivatives, and in particular to compositions comprising omega-3 phospholipids in combination with other omega-3 derivatives.  
WO/2014/057484A8
An isolated peptide comprising a Huntingtin (Htt) amino acid sequence being no longer than 15 amino acids, wherein said Htt amino acid sequence comprises the sequence X1X2X3X4X5, wherein X1 is a hydrophobic amino acid or threonine, X2 is...  
WO/2014/059363A1
Oral solution formulations of aripiprazole, methods of manufacture of these formulations, methods of administration, and kits containing same.  
WO/2014/058000A1
The purpose of the present invention is to provide a 5-HT2B receptor antagonist which does not induce problematic adverse side effects or the like and can be used safely. Provided are a serotonin 2B receptor antagonist and a prophylactic...  
WO/2014/058875A2
Methods and compositions for enhancing one or more of: myelination, re- myelination, oligodendrocyte numbers, or neuroaxonal protection, while ameliorating an inflammatory condition in a human subject are disclosed. In certain embodiment...  
WO/2014/056710A1
The present invention relates to ethynyl derivatives of formula (I) wherein • R is phenyl, 3-fluorophenyl, 4-fluorophenyl or 2,5-di-fluorophenyl; • or to a pharmaceutically acceptable acid addition salt, in enantiomerically pure form...  
WO/2014/056816A1
The present invention relates to a combination of an Aβ antibody and a BACE1 inhibitor.  
WO/2014/057435A1
The present invention relates to [ortho bi-(hetero-)aryl]-[2-(meta bi-(hetero-)aryl)-pyrrolidin-1-yl]- methanone derivatives of formula (I) wherein R, and the rings A1 A2 and A3 are as described in the description, to pharmaceutically ac...  
WO/2014/059029A1
Disclosed herein are novel compositions and methods for the treatment of age- related diseases, mitochondrial diseases, the improvement of stress resistance, the improvement of resistance to hypoxia and the extension of life span. Also d...  
WO/2014/053418A2
The present invention relates to a method for obtaining mesenchymal stem cells (MSCs) from mammalian tissue or body fluid, comprising isolating said MSCs from tissue or body fluid and expanding said isolated MSCs in multiple cultivation ...  
WO/2014/055588A1
The present invention relates to methods of treatment using [3-(4-{2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1H-imidazol-4 -yl}-phenoxy)-propyl]-diethyl amine ("COMPOUND I") or a pharmaceutically acceptable salt thereof. In various embodim...  
WO/2014/054635A1
Provided is a therapeutic agent for diseases associated with a cholinergic property of the central nervous system (CNS) and/or the peripheral nervous system (PNS), diseases associated with the contraction of smooth muscle, incretion dise...  
WO/2014/055541A1
The number of acne lesions in a human subject is reduced by administering to the subject a pharmaceutical composition that includes a pharmaceutically acceptable carrier and a therapeutically effective amount of an agent that selectively...  
WO/2014/055977A3
The plasma concentration of at least one branched chain amino acid in a mammal in need of such reduction is reduced by administering an agent that increases the plasma concentration of large neutral amino acids. The invention also includ...  

Matches 701 - 750 out of 103,184